Short answer
Cencora (COR) filed its Q4 2025 10-Q quarterly report on Feb 4, 2026 for the quarter ended Dec 31, 2025. Quarterly revenue was $85.9B (up 5.5% year over year) with net income of $560M.
Q4 2025 key financials · XBRL
- Revenue
- $85.9B
- +5.5% YoY
- Net income
- $560M
- +14.5% YoY
- Operating margin
- 0.9%
- Gross margin
- 3.6%
- EPS (diluted)
- $2.87
- +14.8% YoY
Source: XBRL data from the Cencora (COR) Q4 2025 10-Q on SEC EDGAR. USD.
Cencora Q4 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $85.9B, up 5.5% YoY (+$4.4B); U.S. Healthcare Solutions +5.0% ($3.7B), International Healthcare Solutions +9.6% ($0.7B)
- Gross profit $3.07B, up 20.1% YoY; U.S. Healthcare Solutions margin 2.47% (+46 bps), International Healthcare Solutions +3.3% gross profit increase
- Operating income $760M, up 7.7%; U.S. Healthcare Solutions +21.0%, margin 1.09% (+14 bps); International Healthcare Solutions down 13.9%
- Operating cash flow used $2.3B vs $2.7B prior year; capital expenditures $119M vs $106M; $4.6B OneOncology acquisition funded by new debt
- Management highlights strategic business reorganization, OneOncology acquisition integration, expects $900M capex in fiscal 2026, notes opioid litigation payments over 13 years totaling $4.3B
Risk Factors
- No material changes in risk factors compared to 10-K for fiscal year ended September 30, 2025
- Carried-forward regulatory risk: potential impact of evolving healthcare laws on pricing and reimbursement policies
- Carried-forward market risk: intense competition affecting market share in pharmaceuticals distribution
- Carried-forward liquidity risk: exposure to short-term debt maturities requiring ongoing cash flow management
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Cencora quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.